Johnson & Johnson (NYSE:JNJ), one of many companies vying to be fast to market with a coronavirus vaccine, published encouraging results for its candidate on Thursday. In the journal Nature Medicine, it was reported that pre-clinical studies conducted with the company's Ad26.COV2.S on hamsters indicate that it produced neutralizing antibodies and appeared to block the coronvirus from developing severe clinical disease.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,